Regulation of NF-E2-Related Factor 2 Signaling for Cancer Chemoprevention: Antioxidant Coupled with Antiinflammatory

Rong Hu,¹ Constance Lay-Lay Saw,² Rong Yu,³ and Ah-Ng Tony Kong²

Abstract

Cancer chemoprevention is a process of using either natural or synthetic compounds to reduce the risk of developing cancer. Observations that NF-E2-related factor 2 (Nrf2)-deficient mice lack response to some chemopreventive agents point to the important role of Nrf2 in chemoprevention. Nrf2 is a member of basic-leucine zipper transcription factor family and has been shown to regulate gene expression by binding to a response element, antioxidant responsive element. It is generally believed that activation of Nrf2 signaling is an adaptive response to the environmental and endogenous stresses. Under homeostatic conditions, Nrf2 is suppressed by association with Kelch-like ECH-associated protein 1 (Keap1), but is stimulated upon exposure to oxidative or electrophilic stress. Once activated, Nrf2 translocates into nuclei and upregulates a group of genes that act in concert to combat oxidative stress. Nrf2 is also shown to have protective function against inflammation, a pathological process that could contribute to carcinogenesis. In this review, we will discuss the current progress in the study of Nrf2 signaling, in particular, the mechanisms of Nrf2 activation by chemopreventive agents. We will also discuss some of the potential caveats of Nrf2 in cancer treatment and future opportunity and challenges on regulation of Nrf2-mediated antioxidant and antiinflammatory signaling in the context of cancer prevention. *Antioxid. Redox Signal.* 13, 1679–1698.

Introduction

DESPITE THE TREMENDOUS PROGRESS in the early detection and treatment of cancer, overall mortality rates for most cancers of epithelial origin have not declined for the past three decades (49). Thus, much attention has been directed to cancer prevention in recent years. Research using animal models has offered better understanding of cancer development. Carcinogenesis can be viewed as a multistep process in which the genes controlling proliferation, differentiation, and apoptosis are transformed and altered under selective environmental pressures (14). Generally speaking, tumor development involves three distinct, yet closely linked, phases: initiation, promotion, and progression (13, 47). The initiation phase is a rapid and irreversible event that occurs when a normal cell is exposed to a carcinogenic event. Often, the unreparable or misrepaired DNA damage happens in the initiation phase. Promotion and progression processes are relatively longer processes than the initiation stage, and are considered re-

versible. By using various animal cancer models (18, 23, 134), scientists found that all three cancer development stages can be intervened by treatment with natural or synthetic chemicals (Fig. 1). Epidemiological and population studies also established a close relationship between incidence of cancer and consumption of certain types of food (147, 169). The term “chemoprevention” was first coined by Michael Sporn in 1976, when he referred to the prevention of malignancy development by vitamin A and its synthetic analogs (141). Since then, chemoprevention has been adopted as one of the major tactics to modulate the process of carcinogenesis (49, 76). Many years of study have proven that this strategy is indeed effective in reducing the incidence of cancer in the well-defined high-risk groups (67, 76). Chemoprevention, hence by definition, is the use of pharmacologic or natural agents to inhibit the development of invasive cancer. The chemicals with a cancer preventive activity are referred to as chemopreventive agents. A chemopreventive agent can inhibit carcinogenesis either by blocking the DNA damage at initiation

¹Department of Physiology, School of Pharmacy, China Pharmaceutical University, Nanjing, China.

²Department of Pharmaceuticals, Center for Cancer Prevention Research, Ernest-Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey.

³Department of Neurosurgery, The Vivian L. Smith Center for Neurologic Research, The University of Texas-Health Science Center at Houston, Houston, Texas.

FIG. 1. Chemopreventive agents that block or suppress multistage carcinogenesis. Carcinogenesis is a multistep process. The initiation step is started by the transformation of the normal cell into a cancer cell (initiated cell). These cells undergo tumor promotion into preneoplastic cells, which progress to neoplastic cells. Chemopreventive agents can interfere with different steps of this process. Some agents inhibit metabolic activation of the procarcinogens to their ultimate electrophilic species, or their subsequent interaction with DNA. These agents therefore block tumor initiation (blocking agents). Alternatively, blocking agents can stimulate the detoxification of carcinogens, leading to their secretion from the body. Other agents suppress the later steps (promotion and progression) of multistage carcinogenesis (suppressing agents). Some agents can act as both blocking and suppressing agents.

stage or by arresting or reversing the processes at promotion and progression stages (49, 76, 141). Nevertheless, an effective chemopreventive agent should be able to interfere with the early stages of carcinogenesis and to eliminate premalignant cells before they become malignant (49, 75, 140, 162).

Most of the chemical substances used in cancer chemoprevention studies are natural phytochemicals found in food (143). On the basis of the inhibition stages, Wattenberg has classified chemopreventive agents into two categories—blocking agents and suppressing agents (161). Blocking agents act by preventing carcinogens from reaching the target sites, from undergoing metabolic activation, or from subsequently interacting with crucial cellular macromolecules such as DNA, RNA, and proteins at initiation stages. Suppressing agents, on the other hand, inhibit the malignant transformation of initiated cells at either the promotion or the progression stage. Some agents may work on all three stages of carcinogenesis, and are hence classified into both categories (Fig. 1).

Many different animal models and cancer cell lines have been used to evaluate the chemopreventive values of phytochemicals, and have led to the discovery of new classes of chemopreventive agents, such as isothiocyanates from cruciferous vegetables, polyphenols from green and black tea, and flavonoids from soybeans (143) (Fig. 2). Progress has been also made in understanding the mode of action of newly identified chemopreventive agents. Exposure to the chemopreventive agents produces certain level of reactive oxygen species (ROS) or electrophiles, and causes mild oxidative/electrophilic stresses in cells (20, 84, 125). Such mild oxidative stresses are sufficient to initiate the signaling pathways that, in turn, can activate a variety of cellular events, such as induction of phase II detoxification enzymes and antioxidant enzymes, expression of tumor-suppressor

genes, and inhibition of cell proliferation and angiogenesis (51). Although the signal transduction pathways in response to oxidative and/or electrophilic stress have been studied extensively for many years, our understanding in the cutting-edge area of redox signaling and cancer chemoprevention is still in its infancy. In this review, we will discuss the current progress in study of NF-E2-related factor 2 (Nrf2) signaling, in particular, the mechanisms of Nrf2 activation by chemopreventive agents. Future challenges on regulation of Nrf2-mediated antioxidant and antiinflammatory signaling in the context of cancer prevention will also be discussed.

Kelch-Like ECH-Associated Protein 1-Nrf2-Antioxidant Responsive Element Signaling

To survive under a variety of environmental or intracellular stresses, eukaryotic cells have developed elaborate yet highly efficient cyto-protective machinery to protect themselves from oxidative or electrophilic challenges (57, 92). Proteins that comprise phase II detoxification and antioxidant enzymes provide an enzymatic line of defense against electrophiles and ROS. Among the family of phase II and antioxidant enzymes are glutathione S-transferase (GST), UDP-glucuronosyltransferase, heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), and glutamate cysteine ligase (gamma glutamylcysteine synthetase). Induction of phase II and antioxidant enzymes are coordinately regulated through a consensus *cis*-element at the 5'-flanking promoter region, named antioxidant responsive element (ARE) (33, 136) or electrophile response element (34) (for simplicity, we will use ARE from here on). ARE-mediated gene expression plays a central role in the cellular defense against cellular oxidative damage. Ample experimental evi-

FIG. 2. Chemical structures of selected chemopreventive agents with ability to activate the NF-E2-related factor 2-antioxidant responsive element signaling pathway.

dence also supports the view that induction of ARE-mediated cytoprotective enzymes is a critical and sufficient mechanism to enable protection against carcinogenesis provoked by environmental and endogenous insults.

One of the key ARE-binding transcription factors is Nrf2 (108). Induction of cytoprotective enzymes in response to ROS, electrophiles, and chemopreventive agents is a cellular event that is highly dependent on Nrf2 protein. By activating Nrf2 signaling, chemopreventive agents are able to increase cellular detoxification and antioxidant enzymes, thereby enhancing removal of reactive carcinogens and blocking carcinogenesis. This hypothesis has been tested in many studies. For example, when investigating the chemoprotective effect of oltipraz in human subjects having a high incidence of liver cancer, Kensler's group found that oral administration of oltipraz significantly enhanced the urinary excretion of the phase II conjugation products of the carcinogen aflatoxin (77). Another study with sulforaphane (SFN), an isothiocyanate present abundantly in cruciferous vegetables, has shown that oral administration of SFN could effectively block benzo[a]pyrene-induced forestomach tumors in ICR mice and this protective effect of SFN was abrogated in the Nrf2 knockout

(Nrf2 KO) mice (31), supporting a critical role of phase II detoxification and antioxidant enzymes in prevention of carcinogenesis by chemopreventive agents.

Given the different chemical nature of Nrf2 inducers (128), a mechanism of activation requiring the interaction of Nrf2 inducers with a structurally complementary receptor appears to be quite unlikely. However, many Nrf2 inducers and chemopreventive agents exhibit prooxidant and electrophilic property and may generate different levels of oxidative stress, depending on their doses. It would be reasonable to speculate that a mild oxidative stress generated by chemopreventive agents at appropriate concentrations is sufficient to activate Nrf2 signaling, but not strong enough to cause any adverse effect such as DNA damage or cells death. Activation of Nrf2 signaling further induces detoxification and antioxidant enzymes, thus protecting cells from damage by more active oxidants or electrophiles, such as carcinogens.

Nrf2 was initially discovered in a screen that utilized a tandem repeat of the consensus AP-1 and NF-E2-binding sequences identified in the 5' locus control region of β -globin gene (108). Nrf2 belongs to basic-leucine zipper (bZip) transcription factor family and has six highly conserved domains

FIG. 3. Schematic representation of the conserved regions in Nrf2 and Keap1. (A) Conserved domains are referred to as Neh domains. The Neh2 domain contains the DLG and the ETGE motifs, which are Keap1 binding motifs. The Neh4 and Neh5 domains act cooperatively to bind the coactivator CREB-binding protein, thereby activating transcription. The Neh6 domain contains two highly conserved regions and acts as a linker domain. The Neh1 domain contains the CNC-bZIP region (CNC-bZIP), which promotes dimerization partners and confers DNA-binding specificity. (B) The Keap1 protein comprises five domains: the NTR; the BTB domain (present in actin-binding proteins and mediates Keap1 homodimerization, which is required for Nrf2 retention in the cytoplasm); the IVR (an especially cysteine-rich region); the DGR (which comprises six Kelch motifs that create multiple protein contact sites). The DGR domain of Keap1 is what combines with the Neh2 region of Nrf2, and the CTR. Functionally important cysteines are illustrated. BTB, broad complex, tramtrack, and bric a brac domain; CNC, Cap 'n' Collar; CTR, C-terminal region; DGR, double glycine/Kelch repeat region; IVR, intervening region; Keap1, Kelch-like ECH-associated protein 1; Neh, Nrf2-ECH homology; Nrf2, NF-E2-related factor 2; NTR, N-terminal region.

ity. (B) The Keap1 protein comprises five domains: the NTR; the BTB domain (present in actin-binding proteins and mediates Keap1 homodimerization, which is required for Nrf2 retention in the cytoplasm); the IVR (an especially cysteine-rich region); the DGR (which comprises six Kelch motifs that create multiple protein contact sites). The DGR domain of Keap1 is what combines with the Neh2 region of Nrf2, and the CTR. Functionally important cysteines are illustrated. BTB, broad complex, tramtrack, and bric a brac domain; CNC, Cap 'n' Collar; CTR, C-terminal region; DGR, double glycine/Kelch repeat region; IVR, intervening region; Keap1, Kelch-like ECH-associated protein 1; Neh, Nrf2-ECH homology; Nrf2, NF-E2-related factor 2; NTR, N-terminal region.

called Nrf2-ECH homology (Neh) domains (Fig. 3A). The Neh1 contains a bZip DNA binding motif that enables Nrf2 to interact other bZip transcription factor and form a heterodimer on ARE (109). The Neh3 domain has been shown to function as a transactivation domain and might be involved in interaction with components of transcriptional apparatus (118). The Neh6 domain may contain a degron that contributes to Nrf2 degradation (107). Neh4 and Neh5 domains are found to cooperatively bind with the KIX and CH3 domains of coactivator CBP and to enhance Nrf2 transcription activity (74). The Neh2 domain located at the N-terminus mediates binding with Kelch-like ECH-associated protein 1 (Keap1), a cytosolic protein that inhibits Nrf2 signaling by promoting Nrf2 degradation through ubiquitin/proteasome pathway (73, 109). Similar to many other transcription factors, Nrf2 is subject to regulation by cellular localization. Under basal condition, majority of Nrf2 molecules are found to be in the cytoplasm. Upon exposure to the oxidative stresses, Nrf2 can quickly translocate into the nucleus (60, 123, 164) and form a heterodimer with small musculoaponeurotic fibrosarcoma (Maf) protein (59), which then binds to ARE and enhances transcription of a group of genes that encode phase II detoxification and antioxidant enzymes (28, 121, 126). Many years of research establish that a signal transduction pathway consisting of Keap1-Nrf2-sMaf-ARE is a primary sensor of the signaling generated by electrophiles and chemopreventive agents, and is essential for elicitation of the antioxidant response.

Keap1

Keap1 plays a central role in the regulation of Nrf2 activity. Keap1 was isolated as a Nrf2-associating protein by using a yeast two-hybrid screening system (35). Knockout of Keap1 resulted in constitutive activation Nrf2 signaling (121, 156, 157). Keap1 is a 69-kDa cytosolic protein with high homology to *Drosophila* actin-binding protein Kelch (61). Pri-

mary sequence and alignment analysis reveals that human Keap1 consists of five domains: (i) the N-terminal region (a.a. 1–66), (ii) broad complex, tramtrack, and bric a brac domain (BTB, a.a. 67–178), (iii) an cysteine-rich intervening region (IVR, a.a. 179–321), (iv) double glycine/Kelch repeat region (DGR a.a. 322–608), and (v) C-terminal region (CTR, a.a. 609–625) (29) (Fig. 3B). Keap1 was observed to locate mainly in the cytoplasm, presumably by association with F-actin or myosin VIIa through the Kelch domain (61, 69, 70, 153). Accordingly, Keap1 is hypothesized to be a cytosolic anchor protein that sequesters Nrf2 in cytoplasm under the unstimulated condition. Site-directed mutagenesis of a conserved serine (S104A) within the Keap1 BTB domain revealed that Nrf2 is indeed sequestered in cytoplasm by Keap1 (182). A recent study using transgenic animal-originated cells demonstrated that direct interaction between the Neh2 domain of Nrf2 and Kelch repeat domain of Keap1 is essential for retaining of Nrf2 in the cytoplasm by Keap1 (70). Keap1 also contains a strong nuclear exporting signal (NES) sequence in the IVR domain, which may play a major role in determining the subcellular distribution of Keap1 (72, 142, 154). Keap1 is identified to be associated with Cullin-3, a scaffold protein responsible for formation of an ubiquitin ligase E3 complex (25, 36, 87, 177). It is now clear that Keap1 may not only dictate Nrf2 localization, but also actively targets Nrf2 to degradation.

Due to its high cysteine content, Keap1 was proposed to be the sought-after sensor of ARE inducers soon after its discovery as a suppressor of Nrf2 transcriptional activity (128). Convincing evidence has since accumulated that the cysteine residues in Keap1 indeed play an important role in sensing the presence of ARE inducers and oxidative stress. Several independent studies have demonstrated that the sulfhydryl groups of several Keap1 cysteine residues can be directly modified by oxidation, reduction, or alkylation. Among these cysteine residues, Cys151, 273, and 288 appear

to be essential for regulating Nrf2 function (90, 102, 168, 176). Mutation of Keap1 Cys151 to Ser did not affect Nrf2 degradation by Keap1, but abolished response to electrophiles and oxidants (176). The role of Cys151 in repression of Nrf2 ubiquitination by electrophiles or oxidants has been verified *in vivo* (168). Mutation of either Cys273 or Cys288 residues prevented Keap1 from degrading Nrf2 protein, pointing to a critical role of these cysteine residues in Keap1-mediated Nrf2 ubiquitination (150, 176). A recent study confirmed that the Cys273 and Cys288 amino acids are essential for Nrf2 degradation by Keap1; however, mutation of these two cysteine residues does not affect interaction of Nrf2 and Keap1 (88). Further, both C273A and C288A mutants are able to complement each other in degradation of Nrf2 protein when coexpressed in cells (156). However, later, the same laboratory has reported that simultaneous expression of C273A and C288A mutant proteins in mice could not rescue *Keap1* null mice from juvenile lethality and repress Nrf2 at all (168). Putting together, these studies demonstrate the significance of multiple Keap1 cysteine residues in sensing the presence of oxidants and electrophiles, although it is not clear how the modification of those cysteine residues alters Keap1 function.

Like Nrf2, Keap1 also was reported to be subject to ubiquitination, but its degradation was proteasome independent, which may play a role in activation of Nrf2 signaling by ARE inducers (178). However, different ARE inducers appear to have very different effects on Keap1 ubiquitination and stability. Zhang *et al.* first proposed that *tert*-butylhydroquinone (tBHQ)-induced ubiquitination of Keap1 results in increased degradation of Keap1 by a proteasome-independent mechanism. They observed that, unlike tBHQ, SFN treatment did not cause any Keap1 ubiquitination and degradation. They also noted that the increased Keap1 degradation occurred through a pathway independent of C151, which has been shown to be essential for regulation of Nrf2 degradation. Other groups also observed effects of ARE inducers on Keap1 ubiquitination and stability. For example, Hong *et al.* (48) noted that electrophilic adduction to Keap1 cysteine residues coincided with the increase of Keap1 ubiquitination at K298 and stabilization of Nrf2 protein in the cells exposed to N-iodoacetyl-N-biotinylhexylenediamine. Treatment of HepG2 cells with quercetin was found also to decrease endogenous Keap1 levels, although change in Keap1 ubiquitination was detected (145). These studies suggest that ubiquitination and subsequent degradation of Keap1 might be a mechanism of Nrf2 induction after exposure to certain ARE inducers. However, further studies are needed to clarify whether the different findings are consequence of using different cell lines or different ARE inducers. Studies are also needed to determine whether medication of Keap1 cysteine residues play the role in Keap1 ubiquitination.

The "hinge and latch" two-site binding model

Keap1 is characterized as a substrate adaptor protein for a cullin-3-based ubiquitin E3 ligase and is essential for ubiquitination of Nrf2 (25, 36, 87, 177). Keap1 has two functional domains: the Kelch/DGR domain, which binds Nrf2, and the BTB domain, which is responsible for homodimerization and

interaction with the N-terminus of cullin-3 (25, 36, 87, 177). On the basis of sequence homology and mutation analyses (73, 89, 107), it was reported that Nrf2 has two Keap1 binding motifs in the Neh2 domain: an ETGE motif, which locates at the N-terminal region and is important for ubiquitination of Nrf2 (73, 107), and a DLG motif, which is essential for interacting with Keap1 (89) (Fig. 3A). The ETGE motif and the DLG motif mediate a cooperative binding to Keap1. Deletion of the ETGE motif significantly weakened Keap1 binding mediated by the DLG motif; therefore, the ETGE motif appears to play a permissive role for the DLG motif. Recently, isothermal calorimetry measurement also detected a two-phase binding between Keap1 and Neh2. The Keap1 binding affinity of the ETGE motif is almost two orders of magnitude stronger than the DLG motif (148). In addition, seven lysine residues of the Neh2 domain, which reside upstream of the ETGE motif, have been shown to be indispensable for Keap1-dependent poly-ubiquitination and degradation of Nrf2 (177).

A "hinge and latch" two-site binding model is proposed (149). Two Keap1 molecules form homodimer *via* their BTB domain (182). The high affinity ETGE motif functions as a hinge to pin down Neh2 to Keap1, while the low affinity DLG motif functions as a latch. Linking the hinge and the latch motif is a lysine-rich central α -helix. In this nine-turns α -helix, six of seven lysine residues are located on one side of the helical surface (148). Since these lysine residues are targets for Keap1-mediated ubiquitination by E3 ligase (177), these lysine residues are speculated to be biologically important for the regulation of Nrf2 stability. When the latch is in position, it helps to set the central α -helix in an adequate orientation to expose these lysine residues (177).

The two-site binding is relatively unstable. The low affinity latch binding may be more vulnerable to the conformation change of Keap1 dimer resulted from oxidative modification. It is proposed that the DLG motif may possess the signaling switch for the repressive regulation of Nrf2 *via* the Keap1-dependent ubiquitination and proteasomal degradation. The switch from two-site binding to one-site binding may explain the observed facts that the inhibition of Nrf2 degradation is not at the expense of Keap1/Nrf2 binding. Only recently, the X-ray crystallography structure of mouse Keap1 homodimer was reported. Three-dimensional reconstruction at 2.4-Å resolution revealed two large spheres attached by short linker arms to the sides of a small forked-stem structure, resembling a cherry-bob. Each sphere has a tunnel corresponding to the central hole of the β -propeller domain, as determined by X-ray crystallography. The IVR domain appears to surround the core of the β -propeller domain. The unexpected proximity of IVR to the β -propeller domain suggests that any distortions generated during modification of reactive cysteine residues in the IVR domain may send a derepression signal to the β -propeller domain and thereby stabilize Nrf2. This study thus provides a structural basis for the two-site binding and hinge-latch model of stress sensing by the Nrf2-Keap1 system (120).

Nrf2

In human Nrf2 protein, one bipartite nuclear localization signal (NLS) was identified in the basic region, named bipartite nuclear localization signal at the basic region (bNLS)

(62, 100). In addition, a monopartite NLS was characterized at the amino-terminus (NLS_N) and another monopartite NLS was identified at the carboxyl-terminus (NLS_C) of human and murine Nrf2 (146). One NES was characterized in the ZIP dimerization domain, named NESzip (62, 100). Recently, another NES was characterized in the Neh5 transactivation (TA) domain, named NES_{TA} (103). In full-length wild-type (WT) Nrf2, the combined nuclear exporting activities of NES_{TA} and NESzip appear to be able to counter balance the nuclear importing activities mediated by bNLS, NLS_N, and NLS_C motifs. We have shown that when expression of a green fluorescence protein (EGFP)-tagged Nrf2 was enhanced in HeLa cells, a heterogeneous distribution pattern of EGFP-Nrf2 was observed. Nearly 60% cells showed whole cell distribution, 30% cells showed nuclear distribution, and 12% cells showed cytosolic distribution (103). Mutation of single key leucine residue in the NES motif, such as L184 in the NES_{TA} motif and L544 in the NESzip motif, was sufficient to abolish their nuclear exporting activity (100, 103). Mutation of either the L184 residue or the L544 residue in full-length Nrf2 was sufficient to convert the heterogeneous distribution pattern (103), suggesting that both the NES_{TA} and NESzip motifs are indispensable for balancing the effect of bNLS, NLS_N, and NLS_C motif. We also found that the NES_{TA} motif was redox sensitive (103), but not the bNLS motif and the NESzip motif (100). The redox sensitivity of the NLS_N and NLS_C motif has not been determined and was speculated to be redox insensitive, since no cysteine residue exists in these two NLS motifs (102).

As discussed above, Nrf2 contains a redox-sensitive NES motif; it is, therefore, reasonable to assume that Nrf2 by itself

can sense and transduce redox signaling. We speculate that, under homeostatic conditions, both the NLS and the NES counteract each other and reach a dynamic balance; as a result, Nrf2 exhibits whole cell distribution. The presence of Nrf2 in nuclei may account for the basal or constitutive Nrf2 activities. When challenged with oxidative stress, the redox-sensitive NES_{TA} is disabled, whereas the redox-insensitive NLS remains functional (15, 100), leading to predominant nuclear distribution of Nrf2. Nrf2 consists of a constitutively active NESzip bNLS-NLS_N-NLS_C tandem and a conditional NES_{TA} motif. The NES_{TA} motif may function as a redox-sensitive switch to determine Nrf2 localization under different redox conditions.

A redox-signaling model of the antioxidant response

Accumulating evidence showed that Keap1-mediated Nrf2 ubiquitination is highly sensitive to redox status, although Keap1/Nrf2 dissociation is relatively insensitive. Nrf2 nuclear translocation also has high redox sensitivity. Accordingly, we propose a redox-signaling model for activation of Nrf2 signaling by oxidative stress (Fig. 4). There are two pools of Nrf2 proteins in cells: the free-floating Nrf2 (fNrf2) and the Keap1-binding Nrf2 (kNrf2). Under homeostatic condition, kNrf2 are constantly degraded through ubiquitin/proteasome pathway, and cells will maintain a relatively small size of fNrf2 pool when the equilibrium is reached between Nrf2 synthesis and its degradation. However, upon exposure to oxidative stress, the Keap1-mediated redox-sensitive Nrf2 ubiquitination and degradation is impeded, and the pool of fNrf2 proteins begins to expand (129, 175, 178). The fNrf2 proteins can further respond to the redox signals and translocate into the

FIG. 4. Hypothetic model of Nrf2-mediated redox signaling. There are two pools of Nrf2 proteins, fNrf2 and kNrf2. Under homeostatic conditions (A), kNrf2 binds to Keap1 dimer *via* a high affinity ETGE (hinge) motif and a low affinity DLG (latch) motif. The two-site binding exposes the Ub-acceptor site(s) in Nrf2. Ubiquitinated Nrf2 proteins are destined to proteasomal degradation. There appears to be an equilibrium between protein synthesis and degradation. As a result, there is only a small pool of fNrf2, contributing to basal activation. When stimulated by oxidative stress or upstream kinases (B), the conformation change of the Keap1 dimer, probably *via* intermolecular disulfide bond formation, disrupts the two-site binding. As a result, the Ub-acceptor site(s) is/are not easily accessible. The ubiquitination and the proteasomal degradation of Nrf2 are impeded and Keap1 is saturated by kNrf2. Nrf2 protein synthesis, however, is elevated. As a consequence, the pool of fNrf2 expands and it can transmit redox signals to cell nucleus *via* gradient nuclear translocation. fNrf2, free-floating Nrf2; Keap1, Kelch-like ECH-associated protein 1; kNrf2, Keap1-binding Nrf2; Nrf2, NF-E2-related factor 2; Ub, ubiquitination.

nucleus. On the basis of this model, the size of fNrf2 pool is believed to be a key determinant of the magnitude of antioxidant response (170). If cells have more fNrf2, same amount of ROS may elicit more Nrf2 influx into the nucleus and consequently induce a stronger antioxidant response. Thus, it would be more reasonable to hypothesize that both Keap1 and Nrf2 are functioning as redox sensors in response to oxidative stress.

This model may explain the chemoprotective effect of phase II enzyme inducers. Treatment with a low dosage of phase II enzyme inducers can impede Keap1-mediated ubiquitination of Nrf2 and expand the fNrf2 pool. As such, the phase II inducers exert a priming effect to tune up the overall redox sensitivity of the cell. Once the cell confronts oxidative stress, it can readily initiate an effective antioxidant response to neutralize the oxidative toxicity and restore redox homeostasis.

Regulation of Nrf2 signaling by other pathways

Other signaling pathways have been reported to influence Keap1-Nrf2-sMaf-ARE signaling, among which are several kinases, such as protein kinase C (PKC), mitogen-activated protein kinases (MAPKs), phosphatidylinositol 3-kinase (PI3K), and PKR-like endoplasmic reticulum kinase (PERK) (24, 53, 99, 170). Activation of the extracellular signal-regulated protein kinase 2 (ERK2) and c-Jun NH(2)-terminal kinase-1 (JNK1) pathway appeared to enhance Nrf2 signaling (6, 137, 167, 170, 171, 180, 181). In contrast, the activation of the p38 MAPK pathway appeared to inhibit Nrf2 signaling (79, 137, 172, 181). Most recently, it was found that phosphorylation of Nrf2 by p38 increases Keap1/Nrf2 binding (79). This finding suggests that p38 may inhibit Nrf2 signaling by enhancing Keap1 sequestering of Nrf2 in cytoplasm. By using a cell-free system, Huang *et al.* have demonstrated that PKC can directly phosphorylate Nrf2 at Serine 40 (52), thereby promoting its dissociation from Keap1 (16, 53, 119). PI3K is also reported to play a role in Nrf2 activation (68, 69, 99, 113). In response to oxidative stress, PI3K signaling is activated and results in depolymerization of actin microfilaments, which somehow facilitates Nrf2 nuclear translocation (69). PERK has been shown to phosphorylate Nrf2 and enhance its nuclear translocation by disrupting Keap1 binding (24).

Several coactivators, like p160 and CBP/p300, are shown to interact with the Nrf2-Maf-ARE complex and enhance Nrf2 transcriptional activity (74, 179). A recent study shows that activation of ERK and JNK pathways promotes recruitment of coactivator to the transcription initiation complex and upregulates Nrf2 transcriptional activity (137).

Nrf2 and Chemoprevention

Cancer has been reported to be a leading cause of death in the United States (64). As discussed earlier, carcinogenesis is a multistep process, thus providing numerous opportunities for cancer prevention. At this time, prevention could be very costly, but it could be the best approach toward cancer managements. It is estimated that it would cost clinical prevention in the United States from under \$US2,000 to over \$US6,000,000 per life-year saved (54). Even so, American society would appear to be willing to pay for such costly cancer prevention programs since the disease inflicts great pains and

the burden for treatment is overwhelming. The good news is, cancer is a preventable disease. After going through the review of previous section on Keap-Nrf2-ARE signaling, it is timely to enter into the topic on regulation of Nrf2 signaling for cancer chemoprevention.

Current studies have shown that some chemopreventive compounds are not only effective in animal models, but also promising in the on-going clinical trials (50). In general, chemopreventive compounds may work *via* multifaceted molecular pathways (4, 46, 66), such as by suppressing inflammation, cell proliferation, invasion, and angiogenesis of tumor cells (5), and by enhancing the antioxidant response (102, 174). A growing body of evidence justifies that targeting the Nrf2 pathway is a viable approach in cancer prevention (82, 83, 94, 112).

The first *in vivo* evidence showing a critical role of Nrf2 in induction of phase II detoxification enzymes was published in 1997 (58). By using Nrf2-deficient (Nrf2 KO) mice, Ito *et al.* found that the magnitude of *GST* and *NQO1* induction was significantly lower in the Nrf2-deficient mice than that in Nrf2 heterozygous mice. Such a critical role of Nrf2 in activation of phase II antioxidant genes has been further confirmed in many studies using Nrf2-deficient mice (Table 1). An immediate application of this finding in cancer prevention is to test the anticarcinogenic activity of chemopreventive compounds in Nrf2 KO mice. Figure 5 has shown how the Nrf2 pathway protects mice from carcinogen-induced neoplastic transformation. As Nrf2 is disrupted, induction of cytoprotective phase II enzymes is impaired. When Nrf2 KO mice are exposed to carcinogens, the uncontrollable oxidative stress generated by carcinogens would damage DNA and induce persistent inflammation, which, in turn, increases genomic instability and enhance neoplastic transformation. In comparison with Nrf2 KO mice, the WT mice maintain normal induction of phase II detoxification enzymes, and hence limit the cytotoxic effect of carcinogen-generated oxidative stress. Many chemopreventive compounds have been shown to induce phase II detoxification enzymes through a mechanism dependent on Keap1-Nrf2-ARE signaling (Fig. 2). Thus, it has been hypothesized that chemopreventive agents may act as oxidants or electrophiles to modify several key cysteine residues of Keap1, thereby preventing Nrf2 degradation; meanwhile, chemopreventive-agent-generated redox signal may directly act on Nrf2 molecules and enhance their nuclear localization. Given the important role of Nrf2 in protection against carcinogenesis, attempts have been made to develop more effective chemopreventive agents by targeting Nrf2 pathway.

Nrf2 and Antiinflammation–Nrf2 KO-Dextran Sulfate Sodium and Azoxymethane-Dextran Sulfate Sodium Colon Model

Current studies have linked chronic inflammation to cancer development (105). Colorectal cancer (CRC) is one of the classic examples that demonstrate a close relationship between chronic inflammation and carcinogenesis (106) (Fig. 6A). Treatment of animals with dextran sulfate sodium (DSS) has been shown to induce colitis, a chronic inflammatory disease, whereas treatment of animals with both azoxymethane (AOM) and DSS induces CRC. Using Nrf2 KO mice, we found that disruption of Nrf2 gene renders animals

TABLE 1. DEPENDENCY OF CARCINOGENESIS AND CHEMOPREVENTION ON Nrf2-KNOCKOUT *In Vivo* MODELS

<i>Carcinogen/chemopreventive compounds</i>	<i>Model</i>	<i>Phenotype/outcome</i>	<i>Reference</i>
Phenolic antioxidant butylated hydroxyanisole	Heterozygous/homozygous Nrf2 KO mice	The magnitude of the induction of <i>GST</i> and <i>NQO1</i> genes was significantly lower in the homozygous Nrf2 KO than in the Nrf2 heterozygous mouse.	58
BaP/oltipraz, a substituted 1,2-dithiole-3-thione (4-methyl-5-[2-pyrazinyl]-1,2-dithiole-3-thione)	Nrf2 WT <i>vs.</i> Nrf2 KO mice	Constitutive hepatic and gastric activities of <i>GST</i> and <i>NQO1</i> ↓ 50%–80% in Nrf2 KO <i>vs.</i> Nrf2 WT mice Nrf2 KO mice had a significantly ↑ burden of gastric neoplasia after treatment with BaP than did WT mice. Oltipraz significantly ↓ multiplicity of gastric neoplasia in WT mice by 55%, but had no effect on tumor burden in Nrf2 KO mice. ↑ BaP-DNA adduct in the forestomach of Nrf2 KO mice	132, 133
D3T/oltipraz	Nrf2 WT <i>vs.</i> Nrf2 KO mice	Hepatic activities of <i>GST</i> and <i>NQO1</i> ↑ by D3T in WT mice but not in Nrf2 KO mice <i>NQO1</i> in liver, forestomach, and kidney ↑ by oltipraz significantly in WT mice but not in Nrf2 KO mice Basal activity of hepatic, forestomach, and kidney <i>NQO1</i> in Nrf2 KO mice was 70% ↓ than in WT mice.	93, 95
BaP/SFN	Nrf2 WT <i>vs.</i> Nrf2 KO mice	↑ significantly BaP-evoked forestomach tumors in Nrf2 KO mice, which was blocked by SFN significantly in WT mice. This protection resulted from ↑ phase II enzymes.	31
Diesel exhaust	Heterozygous/homozygous Nrf2 KO mice	↑ DNA adducts formation in the lungs, severe hyperplasia, and accumulation of the oxidative DNA adduct 8-hydroxydeoxyguanosine in the bronchial epidermis in Nrf2 KO mice	8
BaP	Transgenic mice harboring <i>gpt</i> with heterozygous/homozygous Nrf2 KO mice (<i>nrf2</i> ^{+/-} :: <i>gpt</i> and <i>nrf2</i> ^{-/-} :: <i>gpt</i> mice)	↑ spontaneous mutation of the lung <i>gpt</i> gene in Nrf2 KO mice ↑ the lung mutation frequency 3.1- and 6.1-fold in <i>nrf2</i> ^{+/-} and <i>nrf2</i> ^{-/-} mice, respectively, compared with BaP-untreated <i>nrf2</i> ^{+/-} mice, showing that <i>nrf2</i> ^{-/-} mice are more susceptible to genotoxic carcinogens	7

TABLE 1. (CONTINUED)

<i>Carcinogen/chemopreventive compounds</i>	<i>Model</i>	<i>Phenotype/outcome</i>	<i>Reference</i>
BBN/oltipraz	Nrf2 WT and Nrf2 KO mice	<p>↑ BBN-induced bladder carcinogenesis in Nrf2 KO mice, higher incidence of bladder carcinoma and invasive carcinoma</p> <p>Oltipraz ↓ incidence of bladder carcinoma by BBN in WT but little effects in KO</p> <p>Oltipraz ↑ BBN glucuronidation and decreased the urinary concentration of a carcinogen of BBN and counteract the BBN suppression of <i>UGT1A</i> in the bladder in WT</p>	56
DMBA/TPA/SFN	Nrf2 WT <i>vs.</i> Nrf2 KO mice	<p>↑ skin tumorigenesis in Nrf2 KO mice than WT</p> <p>Nrf2 and <i>HO-1</i> ↓ in skin tumors</p> <p>SFN significantly inhibits skin tumorigenesis in WT but not in KO.</p>	166
DMBA/TPA/tBHQ	Nrf2 WT and transgenic mice with overexpression of dominant-negative Nrf2 mutant in the epidermis under the control of the K14-dnNrf2	↑ onset, incidence, and multiplicity of DMBA/TPA induced skin papillomas in K14-dnNrf2 mice	9
DSS	Nrf2 WT <i>vs.</i> Nrf2 KO mice	<p>Nrf2 KO mice had significantly shorter colon than Nrf2 WT mice ($p < 0.05$).</p> <p>↑ DSS-induced colitis, ↓ <i>HO-1</i>, <i>NQO1</i>, <i>UGT1A1</i>, <i>GSTM1</i>, ↑ proinflammatory mediators/cytokines: <i>COX-2</i>, <i>iNOS</i>, <i>iL-1b</i>, <i>iL-6</i></p>	80
AOM-DSS	Nrf2 WT <i>vs.</i> Nrf2 KO mice	<p>↑ colonic tumor <i>vs.</i> 53% Nrf2 WT ($p < 0.05$) in Nrf2 KO, ↑ <i>COX-2</i>, <i>5-LOX</i>, <i>PGE₂</i>, <i>LTB₄</i>, <i>inflamed colonic mucosa</i> (<i>nitrotyrosine expression</i>)</p>	81
AOM/DSS	Nrf2 WT and Nrf2 KO mice	<p>↑ <i>NQO1</i>, <i>UGT1A1</i> in WT mice</p> <p>DSS treatment significantly increased ACF, inflammation, and mucosal damage in Nrf2 KO mice, but not WT ($p < 0.05$).</p>	122
IQ	Nrf2 WT and Nrf2 KO mice	<p>↑ incidence and multiplicity of hepatocellular adenoma and carcinoma in Nrf2 KO, ↓ <i>UGT</i>, and <i>GST</i> activities as compared to WT</p>	85

ACF, aberrant crypt foci; AOM, azoxymethane; BaP, benzo[a]pyrene; BBN, *N*-nitrosobutyl(4-hydroxybutyl)amine; D3T, 3*H*-1,2-dithiole-3-thione; DMBA, 7,12-Dimethylbenz(a)anthracene; DSS, dextran sulfate sodium; *gpt*, guanine phosphoribosyltransferase; *GST*, glutathione S-transferase; *HO-1*, heme oxygenase-1; IQ, 2-amino-3-methylimidazo[4,5-*f*]quinoline; K14, keratin 14; Nrf2, NF-E2-related factor 2; KO, knockout; *NQO1*, NAD(P)H:quinone oxidoreductase 1; SFN, sulforaphane; tBHQ, *tert*-butylhydroquinone; TPA, 12-O-tetradecanoylphorbol-13-acetate; *UGT*, UDP-glucuronosyltransferase; WT, wild type.

FIG. 5. Schematic presentation showing that Nrf2-disrupted mice (Nrf2 KO) have a higher susceptibility to carcinogenesis. The critical role of Nrf2 in protecting mice from neoplastic transformation when subject to oxidative stress and carcinogens is intact in Nrf2 WT mice having functional Nrf2-ARE signaling, by enhancing expression of detoxifying metabolizing enzymes and maintaining oxidative stress homeostasis by producing antioxidative stress enzymes. Application of chemopreventive compounds in Nrf2 WT mice can further enhance expression of phase II detoxifying and antioxidant enzymes by regulating the Nrf2-ARE signaling. ARE, antioxidant responsive element; Nrf2, NF-E2-related factor 2; Nrf2 KO, Nrf2 knockout; Nrf2 WT mice, wild-type mice with intact Nrf2 function.

more susceptible to DSS-induced colitis and to AOM-DSS-induced colon carcinogenesis (80, 81). Similar results were obtained by Kensler's group when investigating the role of Nrf2 in prevention of inflammation-associated aberrant crypt foci (ACF) formation (122). They noted that Nrf2 KO mice developed significantly higher incidence of colonic tumor than WT mice. Further, AOM-DSS-treated Nrf2 KO mice had more severe colitis and higher incidence of prolapsed rectum and bleeding than WT mice. Therefore, Nrf2 pathway appears to mediate a strong antiinflammatory response, besides induction of detoxification and antioxidant enzymes as described above.

Regulation of Nrf2-Target Genes in Transgenic Adenocarcinoma Mouse Prostate Mice Prostate Cancer Model

Prostate cancer as a major health concern

Prostate cancer (PCa) remains the top leading cancer types responsible for 25% of new cancer cases with an estimated 192,280, and is second leading cause of cancer death in men, estimated 27,360 deaths in the United States in 2009 (64). Presently, metastatic PCa is not curable and is associated with a mean survival of 2–3 years. Development of PCa is often characterized by a relatively long latent period from the precursor lesions, called prostatic intraepithelial neoplasia (PIN), to the invasive carcinoma and metastasis that is typically associated with age and elderly men (1, 26, 86, 91, 96, 115–117, 124, 165). Therefore, to decrease the incidence of PCa, or to delay the neoplastic development, or to slow the progression of PCa to late stage aggressive diseases achieved through ei-

FIG. 6. A simplified illustration shows the carcinogenesis in human CRC and the role of Nrf2 in antiinflammation and oxidative stress. (A) Pathways that connect inflammation and CRC in AOM/DSS animal model, a chemical-carcinogen-induced CRC model. (B) Role of Nrf2 in protecting inflammation-associated cancer, showing a potential strategy for prevention of inflammation-associated cancers. When the Nrf2 signaling pathway is activated, activation of expression of phase II antioxidant and detoxifying enzymes such as *HO-1*, *NQO1*, *UGT*, and *GST* alike in Nrf2 WT animals can reduce the oxidative stress, and it is postulated that Nrf2 could also regulate proinflammatory genes and cytokines such as *iNOS*, *COX-2*, and *iL-6* alike, and together, they protect the animal from developing inflammation-associated cancer, such as CRC (broken arrows). In contrast, Nrf2 KO animals do not possess functional Nrf2 and Nrf2 signaling pathway; after prolonged inflammatory and oxidative stress caused by AOM/DSS, they have increased incidence, multiplicity, and size of all colorectal tumors, including adenoma and adenocarcinoma as compared with WT animals (solid arrows). ACF, aberrant crypt foci; AOM, azoxymethane; CRC, colorectal cancer; DSS, dextran sulfate sodium; *GST*, glutathione S-transferase; *HO-1*, heme oxygenase-1; Nrf2, NF-E2-related factor 2; Nrf2 KO, Nrf2 knockout; Nrf2 WT mice, wild-type mice with intact Nrf2 function; *NQO1*, NAD(P)H:quinone oxidoreductase 1; *UGT*, UDP-glucuronosyltransferase.

ther dietary or chemical intervention would be logical and would be tremendous clinical benefit to hundreds of thousands of men (10). Further, chemoprevention of PCa will be more cost effective than therapeutics designed to treat/cure the disease.

The transgenic adenocarcinoma mouse prostate mouse model for prostate neoplasia

Development of effective chemopreventive compounds against these malignancies is important and requires conclusive evidence from animal models that emulate human cancers. The transgenic adenocarcinoma mouse prostate (TRAMP) mouse is an autochthonous transgenic animal model of PCa that recapitulates the whole spectrum of human prostate tumorigenesis from the earliest PIN lesions to androgen-independent disease (71).

The TRAMP model was originally developed in Norman Greenberg's laboratory using the minimal prostate specific rat probasin promoter to drive expression of the simian virus 40 (SV40) early region tumor antigen-coding region (T, t; large T and small t antigens) specifically in prostatic epithelium (40). The tumor (T) antigens have the ability to induce transformation *in vivo* (19) and have been used successfully in transgenic mice to induce a transformed state in a variety of systems, including pancreas (45), mammary gland (152), and others [reviewed in Adams and Cory (2)]. The large T antigen acts as an oncoprotein through interaction with and inhibition of retinoblastoma (Rb) and p53 tumor-suppressor gene products, whereas the small t antigen interacts with a protein phosphatase (40). At first glance, it appears that this artificially expressed SV40 transgene oncogene may not be an appropriate model for human PCa; however, given that the loss of WT p53 and Rb has been implicated in the development and progression of PCa (17, 135, 139, 160), this would seem logical. The TRAMP mice express the T antigen oncoprotein by 8 weeks of age and develop distinct pathology in the epithelium of the dorsolateral prostate by 10 weeks of age. TRAMP mice are first observed to develop mild epithelial hyperplasia between 8 and 12 weeks of age. Lymph node metastases can be detected between 18 and 24 weeks of age, and pulmonary metastases were frequently identified by 24 weeks of age. By 28 weeks of age, 100% of the TRAMP mice harbor metastatic PCa in the lymph nodes or lungs (39).

Therefore, the TRAMP model may provide a consistent source of primary and metastatic tumors for histopathobiological and molecular analysis to further define the earliest molecular events involved in the genesis, progression, and metastasis of PCa (38). Further, as seen in human PCa, TRAMP mice develop androgen-independent PCa after castration (38). Overall, the TRAMP model exhibits many similarities to human PCa, including epithelial origin, progression from the PIN stage to adenocarcinoma, and metastasis by a transgene that is hormonally regulated by androgen (38–41), so that it serves as a suitable model (114) (Fig. 7A). PCa, just like CRC, has a critical component of inflammation in the prostate carcinogenesis as well (116, 124). Specifically, for example, immunotherapy consisting of irradiated tumor cell vaccine and anti-CTLA-4 antibodies has been shown to markedly decrease the incidence of prostate tumors in TRAMP mice (55). CTLA-4 is a T cell surface antigen that plays an important role in attenuating T cell activity, and mice treated with anti-CTLA-4 antibodies were found to display a robust immune response to a variety of antigens (98). The same group has continued this work and found that indeed TRAMP mice allowed the functional identification of immunogenic prostate tumor antigens with relevance for

FIG. 7. A simplified illustration shows the pathogenesis in human PCa and the role of Nrf2 in TRAMP PCa model.

(A) Normal prostatic epithelial cells may be subjected to the chronic inflammation and oxidative stress in addition to other factors such as aging and diets. For more detailed molecular pathogenesis of PCa, please refer to Nelson *et al.* (117). As found in CRC, inflammation is believed to be one of the key events before the formation of PCa, and proliferative inflammatory atrophy is a precursor to PIN and PCa. (B) The TRAMP mouse is an autochthonous transgenic animal model of PCa that recapitulates the whole spectrum of human prostate tumorigenesis from the earliest PIN lesions to androgen-independent disease (71). Without chemical or hormonal treatment, 100% of male TRAMP develops PCa and progress from PIN to histological cancer to carcinoma metastasis to lymph nodes, lungs, and occasionally bones sequentially over 12–28 weeks (39, 40). A schematic illustration of the putative role of inflammation and oxidative stress and their effect on Nrf2 and related phase II detoxifying and antioxidant enzymes in prostate carcinogenesis in TRAMP mice. Effective chemopreventive compounds such as COX-2 inhibitors and gamma tocopherol-enriched mixed tocopherols significantly downregulated proinflammatory genes and upregulated expression of Nrf2 and its related detoxifying and antioxidant enzymes, respectively, preventing PCa carcinogenesis in TRAMP mice, especially when they are given early before the formation of PIN. CRC, colorectal cancer; Nrf2, NF-E2-related factor 2; PCa, prostate cancer; PIN, prostatic intraepithelial neoplasia; TRAMP, transgenic adenocarcinoma mouse prostate.

human immunotherapy (32). Further studies with the TRAMP model by Gupta *et al.* have demonstrated a remarkable reduction in the rate of prostate tumorigenesis and metastasis formation between TRAMP mice fed a control diet and those fed a diet supplemented with the COX-2 inhibitor celecoxib (100% *vs.* 25% and 65% *vs.* 0%, respectively) (42). These findings suggest a critical role of proinflammatory enzyme COX-2 in PCa development and progression in the TRAMP model (Fig. 7B).

Nrf2 and GSTs are downregulated in human and TRAMP PCa and regulation of Nrf2-target genes in TRAMP mice by chemopreventive compounds

Importantly, it has been found that from a meta-analysis on 10 human PCa gene expression studies (35), Nrf2 and members of *GSTMu* are extensively decreased statistically. Using the TRAMP transgene and Rb and Nrf2 KO mouse models, the same group has also demonstrated that the loss of Nrf2 initiates a detrimental cascade of reduced GST expression, elevated ROS levels, and ultimately DNA damage associated with tumorigenesis. Our laboratory has also found that tumor progression in TRAMP occurred with a significant suppression of antioxidant enzymes such as catalase, superoxide dismutase, glutathione peroxidase, *HO-1*, and phase II detoxification enzymes, supporting the relevant use of TRAMP in examining Nrf2-related pathways in human PCa (12). Curcumin and phenethyl isothiocyanate alone or in combination significantly decreased the incidence of PCa tumor formation (11), by downregulating Akt signaling pathway, which later was also found in the TRAMP mice treated with broccoli sprout, a rich source of SFN (78). Again, the important role of Nrf2 pathway for effectiveness of SFN in preventing PCa is confirmed in TRAMP mice by inducing expression of Nrf2 and *HO-1*, along with other apoptotic proteins and suppressing Akt-dependent pathways in the prostate of TRAMP mice. Increasing evidence points out that the Akt-dependent signaling regulatory proteins are critical regulators of prostate tumorigenesis *in vivo* (21, 37, 151). Our latest data present the first experimental evidence that inhibition of Akt signaling pathway might be an important cellular mechanism for prevention of prostate tumor growth in TRAMP mice by broccoli sprout. The data also suggest that both the activation of Nrf2 pathway and the inhibition of Akt are required for effective prevention of PCa growth in TRAMP mice (78). Our current understanding of the interplays between Nrf2 and other signaling pathways is incomplete; research is undergoing to shed more light on this aspect.

TRAMP model has been used extensively to evaluate agents against PCa by various chemopreventive compounds, including difluoromethylornithine (43), R-flurbiprofen (163), toremifene (130), green tea (3, 44), genistein (158), and non-steroidal antiinflammatory drugs, celecoxib and exisulind (42, 114), silibinin (131), phenethyl isothiocyanate and curcumin (11), and methyl selenium (159). Most recently, we found that gamma tocopherol-enriched mixed tocopherols suppressed PIN and tumor development in the TRAMP mice, upregulated expression of Nrf2, and induced phase II detoxification and antioxidant enzymes (12). Again, these findings substantiate the important role of Nrf2 pathway in cancer prevention, at least, in TRAMP mice, by chemopreventive agents (Fig. 7B).

Potential epigenomic regulation of Nrf2 in TRAMP mice

The currently accepted paradigm of the regulation of Nrf2 signaling appears to be mainly achieved *via* posttranslational mechanism, as discussed previously. Briefly, Nrf2 is functionally suppressed by Keap1 protein, which binds to and sequesters Nrf2 in the cytoplasm leading to the degradation of Nrf2, and thus prevents Nrf2 to translocate into nucleus to activate its targeted genes (102). When stimulated by oxidative stress or upstream kinases, the ubiquitination and the proteosomal degradation of Nrf2 are impeded and Nrf2 is being released from Keap1, translocates into the nucleus, can dimerize with Maf proteins, binds to ARE, and transcriptionally activates the Nrf2-targeted genes. To date, it is not clear as how expression of Nrf2 in human PCa or in TRAMP mouse tumor is suppressed. However, our most recent studies indicate that expression of Nrf2 is epigenetically silenced by DNA hypermethylation in TRAMP prostate tumor (173), which warrants further studies.

Interplay Between Inflammation and Nrf2 Pathways

Dysfunctional Nrf2 signaling/suppression of Nrf2 in aging TRAMP mice (Fig. 7B) appears to be similar to the Nrf2 KO mice (Fig. 5) and causes a persisting chronic inflammation (Fig. 6B) with increased oxidative stress, and eventually could contribute to and driving carcinogenesis if other factors are

FIG. 8. A simplified scheme illustrating the interplay between Nrf2 and NF- κ B leading to carcinogenesis/chemoprevention. Stimuli from ROS, RNS, and chemopreventive compounds could directly interact with members of upstream kinase signaling pathways such as PI3K, PKC, MAPK, and PERK, especially the MAPKs family, as well as interacting with Nrf2 and NF- κ B pathways concurrently, the potential cross-talk between Nrf2 and NF- κ B is denoted by double-head arrows. Such multiple interactions allow chemopreventive compounds to exert their multiple beneficial cancer preventive properties. MAPK, mitogen-activated protein kinase; NF- κ B, nuclear factor-kappa-B; Nrf2, NF-E2-related factor 2; PERK, PKR-like endoplasmic reticulum kinase; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; ROS, reactive oxygen species; RNS, reactive nitrogen species.

present. Interplay between Nrf2 signaling pathway and inflammatory pathway has recently been reviewed (82, 101). Increasing evidence has shown that Nrf2 could play an important role in defense against oxidative stress possibly by activation of cellular antioxidant machinery as well as suppression of proinflammatory signaling pathways. In addition, *in vivo* and *in vitro* data suggest that many dietary chemopreventive compounds can differentially regulate Nrf2-mediated antioxidant/antiinflammatory signaling pathways as the first line defense or induce apoptosis once the cells have been damaged (101), and many other pathways can also regulate Nrf2, including a wide variety of kinase signaling pathways such as MAPKs, PI3K, PI3K, and PERK as discussed earlier in regulation of Nrf2 signaling by other pathways section (65, 138). Many signaling pathways are involved in the cytokines and inflammatory response, such as nuclear factor-kappa-B (NF- κ B) (30, 127) and MAPKs (155) pathways. Many chemopreventive compounds that act through Nrf2 pathway are also having antiinflammatory activities (82, 83, 101). As an initial study, we explored the relationship between Nrf2 and NF- κ B, a key transcriptional factor involved in inflammatory response (111). Our bioinformatic analysis of the promoter regions of Nrf2 and NF- κ B genes reveals that 75% of the members in the regulatory network are MAPKs, which appears to be consistent with the current role of MAPKs in modulation of both Keap1-Nrf2-ARE (63, 137, 144, 170, 175) and NF- κ B signaling pathways (27, 110). Collectively, we are presenting a simplified model for the potential concerted modulation of Nrf2 and NF- κ B in inflammation and carcinogenesis *via* upstream MAPKs pathway (Fig. 8).

Conclusion and Future Perspective

Many oncogenic transcription factors can be targeted for preventing cancer from forming (22), and Nrf2 is one of the very promising target as evidenced from the findings of increased Nrf2-dependent susceptibility in Nrf2 KO mice to various chemical-carcinogen-induced cancers and the effectiveness of chemopreventive compounds to inhibit carcinogenesis in the counterparts Nrf2 WT mice (with intact Nrf2 function) (Table 1). In addition, the role of Nrf2 in carcinogenesis of PCa in TRAMP mice appears to be implicated with the downregulation of expression of Nrf2 and its target genes (12), which can be explained in part *via* epigenetic mechanism (173). Epigenetic is also modulating the CRC carcinogenesis (104). A variety of antioxidants and antiinflammatory drugs, which are likely to be capable of attenuating procarcinogenic genomic damage from ROS and reactive nitrogen species, are also under current development for PCa prevention (10, 115).

On the other hand, Nrf2-regulated high expression of phase II/antioxidant enzymes during chemotherapy might be one of the major causes of ineffectiveness of chemotherapeutic agents, and such dark side of Nrf2 has been reviewed recently by Zhang's group (97). As we progress with future studies, optimization of the timing of when to give chemopreventive compounds to patients in lieu of the potential dark side of Nrf2 in cancer chemoresistance would need to be considered, in particular with many advanced tumors that are resistance to radiation and chemotherapeutic drugs. Nevertheless, the studies using Nrf2 KO models have clearly shown the protective role of Nrf2 in cancer prevention particularly during

the earlier phases of initiation of carcinogenesis. The dark side of Nrf2 would need further investigation, and may depend on the animal models and the compounds tested. It is believed that basal Nrf2 is indeed a carcinogenesis protective transcriptional factor under normal physiological conditions when it is functioning properly. However, the high levels of Nrf2 as well as many other drug resistance genes, tumor oncogenes, and growth factors found in malignant tumors will need further integration and investigation in terms of translating to patients.

Acknowledgments

This work was supported in part by Grant no.30801410 from the Natural Science Foundation of China (R.H.), NIH R01-CA094828 (A.N.T.K.), and NIH R01-AG023497 (R.Y.). The authors thank all the members of Dr. Tony Kong's lab for their help in the discussion and preparation of this article.

References

1. Abate-Shen C and Shen MM. Molecular genetics of prostate cancer. *Genes Dev* 14: 2410–2434, 2000.
2. Adams JM and Cory S. Transgenic models of tumor development. *Science* 254: 1161–1167, 1991.
3. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, and Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. *Cancer Res* 64: 8715–8722, 2004.
4. Aggarwal BB and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. *Biochem Pharmacol* 71: 1397–1421, 2006.
5. Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB, and Sung B. Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. *Exp Biol Med (Maywood)* 234: 825–849, 2009.
6. Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME, and Tou J. Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. *J Biol Chem* 275: 27694–27702, 2000.
7. Aoki Y, Hashimoto AH, Amanuma K, Matsumoto M, Hiyoshi K, Takano H, Masumura K, Itoh K, Nohmi T, and Yamamoto M. Enhanced spontaneous and benzo(a)pyrene-induced mutations in the lung of Nrf2-deficient gpt delta mice. *Cancer Res* 67: 5643–5648, 2007.
8. Aoki Y, Sato H, Nishimura N, Takahashi S, Itoh K, and Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. *Toxicol Appl Pharmacol* 173: 154–160, 2001.
9. auf dem Keller U, Huber M, Beyer TA, Kumin A, Siemes C, Braun S, Bugnon P, Mitropoulos V, Johnson DA, Johnson JA, Hohl D, and Werner S. Nrf transcription factors in keratinocytes are essential for skin tumor prevention but not for wound healing. *Mol Cell Biol* 26: 3773–3784, 2006.
10. Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, and Nelson WG. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. *Curr Opin Pharmacol* 9: 419–426, 2009.
11. Barve A, Khor TO, Hao X, Keum YS, Yang CS, Reddy B, and Kong AN. Murine prostate cancer inhibition by dietary

- phytochemicals—curcumin and phenylethylisothiocyanate. *Pharm Res* 25: 2181–2189, 2008.
12. Barve A, Khor TO, Nair S, Reuhl K, Suh N, Reddy B, Newmark H, and Kong AN. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. *Int J Cancer* 124: 1693–1699, 2009.
 13. Berenblum I and Armuth V. Two independent aspects of tumor promotion. *Biochim Biophys Acta* 651: 51–63, 1981.
 14. Bertram JS. The molecular biology of cancer. *Mol Aspects Med* 21: 167–223, 2000.
 15. Bloom D, Dhakshinamoorthy S, and Jaiswal AK. Site-directed mutagenesis of cysteine to serine in the DNA binding region of Nrf2 decreases its capacity to upregulate antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. *Oncogene* 21: 2191–2200, 2002.
 16. Bloom DA and Jaiswal AK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from I κ Nrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. *J Biol Chem* 278: 44675–44682, 2003.
 17. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, and Lee WH. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. *Proc Natl Acad Sci U S A* 87: 7762–7766, 1990.
 18. Bosland MC. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. *Eur Urol* 35: 459–463, 1999.
 19. Brinster RL, Chen HY, Messing A, van Dyke T, Levine AJ, and Palmiter RD. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. *Cell* 37: 367–379, 1984.
 20. Chen C, Shen G, Hebbar V, Hu R, Owuor ED, and Kong AN. Epigallocatechin-3-gallate-induced stress signals in HT-29 human colon adenocarcinoma cells. *Carcinogenesis* 24: 1369–1378, 2003.
 21. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, and Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten +/– mice. *Genes Dev* 20: 1569–1574, 2006.
 22. Colburn NH and Kensler TW. Targeting transcription factors for cancer prevention—the case of Nrf2. *Cancer Prev Res (Phila Pa)* 1: 153–155, 2008.
 23. Corpet DE and Pierre F. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. *Cancer Epidemiol Biomarkers Prev* 12: 391–400, 2003.
 24. Cullinan SB and Diehl JA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. *J Biol Chem* 279: 20108–20117, 2004.
 25. Cullinan SB, Gordan JD, Jin J, Harper JW, and Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. *Mol Cell Biol* 24: 8477–8486, 2004.
 26. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, and Nelson WG. Human prostate cancer precursors and pathobiology. *Urology* 62: 55–62, 2003.
 27. de Sousa RR, Queiroz KC, Souza AC, Gurgueira SA, Augusto AC, Miranda MA, Peppelenbosch MP, Ferreira CV, and Aoyama H. Phosphoprotein levels, MAPK activities and NF κ B expression are affected by fisetin. *J Enzyme Inhib Med Chem* 22: 439–444, 2007.
 28. Dhakshinamoorthy S and Porter AG. Nitric oxide-induced transcriptional up-regulation of protective genes by Nrf2 via the antioxidant response element counteracts apoptosis of neuroblastoma cells. *J Biol Chem* 279: 20096–20107, 2004.
 29. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, and Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. *Proc Natl Acad Sci U S A* 99: 11908–11913, 2002.
 30. Dixit V and Mak TW. NF- κ B signaling. Many roads lead to madrid. *Cell* 111: 615–619, 2002.
 31. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, and Lozniewski A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of *Helicobacter pylori* and prevents benzo[a]pyrene-induced stomach tumors. *Proc Natl Acad Sci U S A* 99: 7610–7615, 2002.
 32. Fasso M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, and Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. *Proc Natl Acad Sci U S A* 105: 3509–3514, 2008.
 33. Favreau LV and Pickett CB. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants. *J Biol Chem* 266: 4556–4561, 1991.
 34. Friling RS, Bensimon A, Tichauer Y, and Daniel V. Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. *Proc Natl Acad Sci U S A* 87: 6258–6262, 1990.
 35. Frohlich DA, McCabe MT, Arnold RS, and Day ML. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. *Oncogene* 27: 4353–4362, 2008.
 36. Furukawa M and Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. *Mol Cell Biol* 25: 162–171, 2005.
 37. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, and Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. *Proc Natl Acad Sci U S A* 103: 14477–14482, 2006.
 38. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, and Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. *Cancer Res* 57: 4687–4691, 1997.
 39. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, and Greenberg NM. Metastatic prostate cancer in a transgenic mouse. *Cancer Res* 56: 4096–4102, 1996.
 40. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, and Rosen JM. Prostate cancer in a transgenic mouse. *Proc Natl Acad Sci U S A* 92: 3439–3443, 1995.
 41. Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML, Rosen JM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to

- the prostate in transgenic mice. *Mol Endocrinol* 8: 230–239, 1994.
42. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, Fu P, and Mukhtar H. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. *Cancer Res* 64: 3334–3343, 2004.
 43. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, and Mukhtar H. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. *Cancer Res* 60: 5125–5133, 2000.
 44. Gupta S, Hastak K, Ahmad N, Lewin JS, and Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. *Proc Natl Acad Sci U S A* 98: 10350–10355, 2001.
 45. Hanahan D. Oncogenes in transgenic mice. *Nature* 312: 503–504, 1984.
 46. Hatcher H, Planalp R, Cho J, Torti FM, and Torti SV. Curcumin: from ancient medicine to current clinical trials. *Cell Mol Life Sci* 65: 1631–1652, 2008.
 47. Heidelberger C, Freeman AE, Pienta RJ, Sivak A, Bertram JS, Casto BC, Dunkel VC, Francis MW, Kakunaga T, Little JB, and Schechtman LM. Cell transformation by chemical agents—a review and analysis of the literature. A report of the U.S. Environmental Protection Agency Gene-Tox Program. *Mutat Res* 114: 283–385, 1983.
 48. Hong F, Sekhar KR, Freeman ML, and Liebler DC. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. *J Biol Chem* 280: 31768–31775, 2005.
 49. Hong WK and Sporn MB. Recent advances in chemoprevention of cancer. *Science* 278: 1073–1077, 1997.
 50. Hsu CH and Cheng AL. Clinical studies with curcumin. *Adv Exp Med Biol* 595: 471–480, 2007.
 51. Hu R and Kong AN. Activation of MAP kinases, apoptosis and nutrigenomics of gene expression elicited by dietary cancer-prevention compounds. *Nutrition* 20: 83–88, 2004.
 52. Huang HC, Nguyen T, and Pickett CB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. *Proc Natl Acad Sci U S A* 97: 12475–12480, 2000.
 53. Huang HC, Nguyen T, and Pickett CB. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. *J Biol Chem* 277: 42769–42774, 2002.
 54. Hunt TL, Luce BR, Page MJ, and Pokrzywinski R. Willingness to pay for cancer prevention. *Pharmacoeconomics* 27: 299–312, 2009.
 55. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, and Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. *Cancer Res* 60: 2444–2448, 2000.
 56. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H, and Yamamoto M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. *Cancer Res* 64: 6424–6431, 2004.
 57. Ishii T, Itoh K, Sato H, and Bannai S. Oxidative stress-inducible proteins in macrophages. *Free Radic Res* 31: 351–355, 1999.
 58. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem Biophys Res Commun* 236: 313–322, 1997.
 59. Itoh K, Igarashi K, Hayashi N, Nishizawa M, and Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. *Mol Cell Biol* 15: 4184–4193, 1995.
 60. Itoh K, Tong KI, and Yamamoto M. Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. *Free Radic Biol Med* 36: 1208–1213, 2004.
 61. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes Dev* 13: 76–86, 1999.
 62. Jain AK, Bloom DA, and Jaiswal AK. Nuclear import and export signals in control of Nrf2. *J Biol Chem* 280: 29158–29168, 2005.
 63. Jakubikova J, Sedlak J, Mithen R, and Bao Y. Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. *Biochem Pharmacol* 69: 1543–1552, 2005.
 64. Jemal A, Siegel R, Ward E, Hao Y, Xu J, and Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin* 59: 225–249, 2009.
 65. Jeong WS, Jun M, and Kong AN. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. *Antioxid Redox Signal* 8: 99–106, 2006.
 66. Juge N, Mithen RF, and Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. *Cell Mol Life Sci* 64: 1105–1127, 2007.
 67. Kakizoe T. Chemoprevention of cancer—focusing on clinical trials. *Jpn J Clin Oncol* 33: 421–442, 2003.
 68. Kang KW, Choi SH, and Kim SG. Peroxynitrite activates NF-E2-related factor 2/antioxidant response element through the pathway of phosphatidylinositol 3-kinase: the role of nitric oxide synthase in rat glutathione S-transferase A2 induction. *Nitric Oxide* 7: 244–253, 2002.
 69. Kang KW, Lee SJ, Park JW, and Kim SG. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. *Mol Pharmacol* 62: 1001–1010, 2002.
 70. Kang MI, Kobayashi A, Wakabayashi N, Kim SG, and Yamamoto M. Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. *Proc Natl Acad Sci U S A* 101: 2046–2051, 2004.
 71. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, and Greenberg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. *Prostate* 55: 219–237, 2003.
 72. Karapetian RN, Evstafieva AG, Abaeva IS, Chichkova NV, Filonov GS, Rubtsov YP, Sukhacheva EA, Melnikov SV, Schneider U, Wanker EE, and Vartapetian AB. Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications for expression of oxidative stress-protecting genes. *Mol Cell Biol* 25: 1089–1099, 2005.
 73. Katoh Y, Iida K, Kang MI, Kobayashi A, Mizukami M, Tong KI, McMahon M, Hayes JD, Itoh K, and Yamamoto M. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. *Arch Biochem Biophys* 433: 342–350, 2005.

74. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, and Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. *Genes Cells* 6: 857–868, 2001.
75. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, and Sigman CC. Progress in cancer chemoprevention. *Ann N Y Acad Sci* 889: 1–13, 1999.
76. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, and Sigman CC. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. *Urology* 57: 46–51, 2001.
77. Kensler TW, Curphey TJ, Maxiutenko Y, and Roebuck BD. Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins. *Drug Metabol Drug Interact* 17: 3–22, 2000.
78. Keum YS, Khor TO, Lin W, Shen G, Kwon KH, Barve A, Li W, and Kong AN. Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. *Pharm Res* 26: 2324–2331, 2009.
79. Keum YS, Yu S, Chang PP, Yuan X, Kim JH, Xu C, Han J, Agarwal A, and Kong AN. Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. *Cancer Res* 66: 8804–8813, 2006.
80. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, and Kong AN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. *Cancer Res* 66: 11580–11584, 2006.
81. Khor TO, Huang MT, Prawan A, Liu Y, Hao X, Yu S, Cheung WK, Chan JY, Reddy BS, Yang CS, and Kong AN. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. *Cancer Prev Res (Phila Pa)* 1: 187–191, 2008.
82. Khor TO, Yu S, and Kong AN. Dietary cancer chemopreventive agents—targeting inflammation and Nrf2 signaling pathway. *Planta Med* 74: 1540–1547, 2008.
83. Kim J, Cha YN, and Surh YJ. A protective role of nuclear erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. *Mutat Res* 2009 Sep 30 [Epub ahead of print].
84. Kim SG, Cho MK, Choi SH, Kim HJ, Kwak MK, and Kim ND. Molecular basis for hepatic detoxifying enzyme induction by 2-(allylthio)pyrazine in rats in comparison with oltipraz: effects on prooxidant production and DNA degradation. *Drug Metab Dispos* 27: 667–673, 1999.
85. Kitamura Y, Umemura T, Kanki K, Kodama Y, Kitamoto S, Saito K, Itoh K, Yamamoto M, Masegi T, Nishikawa A, and Hirose M. Increased susceptibility to hepatocarcinogenicity of Nrf2-deficient mice exposed to 2-amino-3-methylimidazo[4,5-f]quinoline. *Cancer Sci* 98: 19–24, 2007.
86. Klein EA and Thompson IM. Update on chemoprevention of prostate cancer. *Curr Opin Urol* 14: 143–149, 2004.
87. Kobayashi A, Kang MI, Okawa H, Ohtsui Y, Zenke Y, Chiba T, Igarashi K, and Yamamoto M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. *Mol Cell Biol* 24: 7130–7139, 2004.
88. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, and Yamamoto M. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. *Mol Cell Biol* 26: 221–229, 2006.
89. Kobayashi M, Itoh K, Suzuki T, Osanai H, Nishikawa K, Katoh Y, Takagi Y, and Yamamoto M. Identification of the interactive interface and phylogenetic conservation of the Nrf2-Keap1 system. *Genes Cells* 7: 807–820, 2002.
90. Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Kaneko H, Nakayama Y, Eguchi M, Wada Y, Kumagai Y, and Yamamoto M. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. *Mol Cell Biol* 29: 493–502, 2009.
91. Kucuk O. Chemoprevention of prostate cancer. *Cancer Metastasis Rev* 21: 111–124, 2002.
92. Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, Yamamoto M, and Kensler TW. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. *Mutat Res* 480–481: 305–315, 2001.
93. Kwak MK, Itoh K, Yamamoto M, Sutter TR, and Kensler TW. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes *in vivo* by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. *Mol Med* 7: 135–145, 2001.
94. Kwak MK and Kensler TW. Targeting NRF2 signaling for cancer chemoprevention. *Toxicol Appl Pharmacol*, 244: 66–76, 2010.
95. Kwak MK, Ramos-Gomez M, Wakabayashi N, and Kensler TW. Chemoprevention by 1,2-dithiole-3-thiones through induction of NQO1 and other phase 2 enzymes. *Methods Enzymol* 382: 414–423, 2004.
96. Landis SH, Murray T, Bolden S, and Wingo PA. Cancer statistics, 1999. *CA Cancer J Clin* 49: 8–31, 1, 1999.
97. Lau A, Villeneuve NF, Sun Z, Wong PK, and Zhang DD. Dual roles of Nrf2 in cancer. *Pharmacol Res* 58: 262–270, 2008.
98. Leach DR, Krummel MF, and Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. *Science* 271: 1734–1736, 1996.
99. Lee JM, Hanson JM, Chu WA, and Johnson JA. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. *J Biol Chem* 276: 20011–20016, 2001.
100. Li W, Jain MR, Chen C, Yue X, Hebbar V, Zhou R, and Kong AN. Nrf2 Possesses a redox-insensitive nuclear export signal overlapping with the leucine zipper motif. *J Biol Chem* 280: 28430–28438, 2005.
101. Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, and Kong AN. Activation of Nrf2-antioxidant signaling attenuates NF-kappaB-inflammatory response and elicits apoptosis. *Biochem Pharmacol* 76: 1485–1489, 2008.
102. Li W and Kong AN. Molecular mechanisms of Nrf2-mediated antioxidant response. *Mol Carcinog* 48: 91–104, 2009.
103. Li W, Yu SW, and Kong AN. Nrf2 possesses a redox-sensitive nuclear exporting signal in the Neh5 transactivation domain. *J Biol Chem* 281: 27251–27263, 2006.
104. Lipkin M, Reddy B, Newmark H, and Lamprecht SA. Dietary factors in human colorectal cancer. *Annu Rev Nutr* 19: 545–586, 1999.
105. Mantovani A, Allavena P, Sica A, and Balkwill F. Cancer-related inflammation. *Nature* 454: 436–444, 2008.
106. McConnell BB and Yang VW. The role of inflammation in the pathogenesis of colorectal cancer. *Curr Colorectal Cancer Rep* 5: 69–74, 2009.

107. McMahon M, Thomas N, Itoh K, Yamamoto M, and Hayes JD. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. *J Biol Chem* 279: 31556–31567, 2004.
108. Moi P, Chan K, Asunis I, Cao A, and Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. *Proc Natl Acad Sci U S A* 91: 9926–9930, 1994.
109. Motohashi H and Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. *Trends Mol Med* 10: 549–557, 2004.
110. Murakami A, Song M, and Ohigashi H. Phenethyl isothiocyanate suppresses receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis by blocking activation of ERK1/2 and p38 MAPK in RAW264.7 macrophages. *Biofactors* 30: 1–11, 2007.
111. Nair S, Doh ST, Chan JY, Kong AN, and Cai L. Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis. *Br J Cancer* 99: 2070–2082, 2008.
112. Nair S, Li W, and Kong AN. Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells. *Acta Pharmacol Sin* 28: 459–472, 2007.
113. Nakaso K, Yano H, Fukuhara Y, Takeshima T, Wada-Isoe K, and Nakashima K. PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. *FEBS Lett* 546: 181–184, 2003.
114. Narayanan BA, Narayanan NK, Pittman B, and Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. *Clin Cancer Res* 10: 7727–7737, 2004.
115. Nelson WG. Agents in development for prostate cancer prevention. *Expert Opin Investig Drugs* 13: 1541–1554, 2004.
116. Nelson WG, De Marzo AM, DeWeese TL, and Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. *J Urol* 172: S6–S11; discussion S-2, 2004.
117. Nelson WG, De Marzo AM, and Isaacs WB. Prostate cancer. *N Engl J Med* 349: 366–381, 2003.
118. Nioi P, Nguyen T, Sherratt PJ, and Pickett CB. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. *Mol Cell Biol* 25: 10895–10906, 2005.
119. Numazawa S, Ishikawa M, Yoshida A, Tanaka S, and Yoshida T. Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. *Am J Physiol Cell Physiol* 285: C334–C342, 2003.
120. Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H, Sato C, and Yamamoto M. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains. *Proc Natl Acad Sci U S A* 107: 2842–2847, 2010.
121. Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler TW, and Yamamoto M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. *Biochem Biophys Res Commun* 339: 79–88, 2006.
122. Osburn WO, Karim B, Dolan PM, Liu G, Yamamoto M, Huso DL, and Kensler TW. Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. *Int J Cancer* 121: 1883–1891, 2007.
123. Osburn WO, Wakabayashi N, Misra V, Nilles T, Biswal S, Trush MA, and Kensler TW. Nrf2 regulates an adaptive response protecting against oxidative damage following diquat-mediated formation of superoxide anion. *Arch Biochem Biophys* 454: 7–15, 2006.
124. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, and Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. *Carcinogenesis* 26: 1170–1181, 2005.
125. Paolini M, Perocco P, Canistro D, Valgimigli L, Pedulli GF, Iori R, Croce CD, Cantelli-Forti G, Legator MS, and Abdel-Rahman SZ. Induction of cytochrome P450, generation of oxidative stress and *in vitro* cell-transforming and DNA-damaging activities by glucoraphanin, the bioprecursor of the chemopreventive agent sulforaphane found in broccoli. *Carcinogenesis* 25: 61–67, 2004.
126. Park EY and Kim SG. NO signaling in ARE-mediated gene expression. *Methods Enzymol* 396: 341–349, 2005.
127. Pomerantz JL and Baltimore D. Two pathways to NF-kappaB. *Mol Cell* 10: 693–695, 2002.
128. Prestera T, Holtzclaw WD, Zhang Y, and Talalay P. Chemical and molecular regulation of enzymes that detoxify carcinogens. *Proc Natl Acad Sci U S A* 90: 2965–2969, 1993.
129. Purdom-Dickinson S, Sheveleva E, Sun H, and Chen QM. Translational control of Nrf2 protein in activation of antioxidant response by oxidants. *Mol Pharmacol* 72: 1074–1081, 2007.
130. Raghoe S, Hooshdaran MZ, Katiyar S, and Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. *Cancer Res* 62: 1370–1376, 2002.
131. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, and Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. *Cancer Res* 68: 6822–6830, 2008.
132. Ramos-Gomez M, Dolan PM, Itoh K, Yamamoto M, and Kensler TW. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. *Carcinogenesis* 24: 461–467, 2003.
133. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, and Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. *Proc Natl Acad Sci U S A* 98: 3410–3415, 2001.
134. Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. *Environ Mol Mutagen* 44: 26–35, 2004.
135. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam S, Yandell DW, and Weichselbaum RR. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. *J Surg Oncol* 46: 31–36, 1991.
136. Rushmore TH and Pickett CB. Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene. Characterization of a xenobiotic-responsive element controlling inducible expression by phenolic antioxidants. *J Biol Chem* 265: 14648–14653, 1990.
137. Shen G, Hebbar V, Nair S, Xu C, Li W, Lin W, Keum YS, Han J, Gallo MA, and Kong AN. Regulation of Nrf2 transactivation domain activity. The differential effects of

- mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein. *J Biol Chem* 279: 23052–23060, 2004.
138. Shen G, Jeong WS, Hu R, and Kong AN. Regulation of Nrf2, NF-kappaB, and AP-1 signaling pathways by chemopreventive agents. *Antioxid Redox Signal* 7: 1648–1663, 2005.
 139. Singh A, Jones RF, Friedman H, Hathir S, Soos G, Zabo A, and Haas GP. Expression of p53 and pRb in bladder and prostate cancers of patients having both cancers. *Anticancer Res* 19: 5415–5417, 1999.
 140. Smith TJ, Hong JY, Wang ZY, and Yang CS. How can carcinogenesis be inhibited? *Ann N Y Acad Sci* 768: 82–90, 1995.
 141. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. *Cancer Res* 36: 2699–2702, 1976.
 142. Sun Z, Chin YE, and Zhang DD. Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. *Mol Cell Biol* 29: 2658–2672, 2009.
 143. Surh YJ. Cancer chemoprevention with dietary phytochemicals. *Nat Rev Cancer* 3: 768–780, 2003.
 144. Svehlikova V, Wang S, Jakubikova J, Williamson G, Mithen R, and Bao Y. Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells. *Carcinogenesis* 25: 1629–1637, 2004.
 145. Tanigawa S, Fujii M, and Hou DX. Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. *Free Radic Biol Med* 42: 1690–1703, 2007.
 146. Theodore M, Kawai Y, Yang J, Kleshchenko Y, Reddy SP, Villalta F, and Arinze JJ. Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2. *J Biol Chem* 283: 8984–8994, 2008.
 147. Tominaga S and Kuroishi T. An ecological study on diet/nutrition and cancer in Japan. *Int J Cancer Suppl* 10: 2–6, 1997.
 148. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, and Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. *Mol Cell Biol* 26: 2887–2900, 2006.
 149. Tong KI, Kobayashi A, Katsuoka F, and Yamamoto M. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. *Biol Chem* 387: 1311–1320, 2006.
 150. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, and Yamamoto M. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. *Mol Cell Biol* 27: 7511–7521, 2007.
 151. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, and Pandolfi PP. Identification of a tumour suppressor network opposing nuclear Akt function. *Nature* 441: 523–527, 2006.
 152. Tzeng YJ, Guhl E, Graessmann M, and Graessmann A. Breast cancer formation in transgenic animals induced by the whey acidic protein SV40 T antigen (WAP-SV-T) hybrid gene. *Oncogene* 8: 1965–1971, 1993.
 153. Velichkova M, Guttman J, Warren C, Eng L, Kline K, Vogl AW, and Hasson T. A human homologue of *Drosophila* kelch associates with myosin-VIIa in specialized adhesion junctions. *Cell Motil Cytoskeleton* 51: 147–164, 2002.
 154. Velichkova M and Hasson T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. *Mol Cell Biol* 25: 4501–4513, 2005.
 155. Wada T and Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. *Oncogene* 23: 2838–2849, 2004.
 156. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, Kang MI, Kobayashi A, Yamamoto M, Kensler TW, and Talalay P. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. *Proc Natl Acad Sci U S A* 101: 2040–2045, 2004.
 157. Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S, Takahashi S, Imakado S, Kotsuji T, Otsuka F, Roop DR, Harada T, Engel JD, and Yamamoto M. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. *Nat Genet* 35: 238–245, 2003.
 158. Wang J, Eltoum IE, and Lamartiniere CA. Genistein alters growth factor signaling in transgenic prostate model (TRAMP). *Mol Cell Endocrinol* 219: 171–180, 2004.
 159. Wang L, Bonorden MJ, Li GX, Lee HJ, Hu H, Zhang Y, Liao JD, Cleary MP, and Lu J. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. *Cancer Prev Res (Phila Pa)* 2: 484–495, 2009.
 160. Wang X, Deng H, Basu I, and Zhu L. Induction of androgen receptor-dependent apoptosis in prostate cancer cells by the retinoblastoma protein. *Cancer Res* 64: 1377–1385, 2004.
 161. Wattenberg LW. Chemoprevention of cancer. *Cancer Res* 45: 1–8, 1985.
 162. Wattenberg LW. What are the critical attributes for cancer chemopreventive agents? *Ann N Y Acad Sci* 768: 73–81, 1995.
 163. Wechter WJ, Leipold DD, Murray ED, Jr., Quiggle D, McCracken JD, Barrios RS, and Greenberg NM. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. *Cancer Res* 60: 2203–2208, 2000.
 164. Wilson LA, Gemin A, Espiritu R, and Singh G. ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response element. *FASEB J* 19: 2085–2087, 2005.
 165. Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN, and Thun MJ. Long-term trends in cancer mortality in the United States, 1930–1998. *Cancer* 97: 3133–3275, 2003.
 166. Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, Conney AH, and Kong AN. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. *Cancer Res* 66: 8293–8296, 2006.
 167. Xu C, Yuan X, Pan Z, Shen G, Kim JH, Yu S, Khor TO, Li W, Ma J, and Kong AN. Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. *Mol Cancer Ther* 5: 1918–1926, 2006.
 168. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H, and Yamamoto M. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. *Mol Cell Biol* 28: 2758–2770, 2008.
 169. Yang CX, Kuroishi T, Huang XE, Inoue M, and Tajima K. Correlation between food consumption and colorectal cancer: an ecological analysis in Japan. *Asian Pac J Cancer Prev* 3: 77–83, 2002.

170. Yu R, Chen C, Mo YY, Hebbar V, Owuor ED, Tan TH, and Kong AN. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. *J Biol Chem* 275: 39907–39913, 2000.
171. Yu R, Lei W, Mandlekar S, Weber MJ, Der CJ, Wu J, and Kong AN. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. *J Biol Chem* 274: 27545–27552, 1999.
172. Yu R, Mandlekar S, Lei W, Fahl WE, Tan TH, and Kong AN. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. *J Biol Chem* 275: 2322–2327, 2000.
173. Yu S, Khor TO, Cheung KL, Li W, Wu TY, Ying H, Foster BA, Kan YW, and Kong AN. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. *PLoS One* 5: e8579, 2010.
174. Yu S and Kong AN. Targeting carcinogen metabolism by dietary cancer preventive compounds. *Curr Cancer Drug Targets* 7: 416–424, 2007.
175. Yuan X, Xu C, Pan Z, Keum YS, Kim JH, Shen G, Yu S, Oo KT, Ma J, and Kong AN. Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. *Mol Carcinog* 45: 841–850, 2006.
176. Zhang DD and Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. *Mol Cell Biol* 23: 8137–8151, 2003.
177. Zhang DD, Lo SC, Cross JV, Templeton DJ, and Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. *Mol Cell Biol* 24: 10941–10953, 2004.
178. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, and Hannink M. Ubiquitination of Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets Keap1 for degradation by a proteasome-independent pathway. *J Biol Chem* 280: 30091–30099, 2005.
179. Zhu M and Fahl WE. Functional characterization of transcription regulators that interact with the electrophile response element. *Biochem Biophys Res Commun* 289: 212–219, 2001.
180. Zipper LM and Mulcahy RT. Erk activation is required for Nrf2 nuclear localization during pyrrolidine dithiocarbamate induction of glutamate cysteine ligase modulatory gene expression in HepG2 cells. *Toxicol Sci* 73: 124–134, 2003.
181. Zipper LM and Mulcahy RT. Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. *Biochem Biophys Res Commun* 278: 484–492, 2000.
182. Zipper LM and Mulcahy RT. The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. *J Biol Chem* 277: 36544–36552, 2002.

Address correspondence to:

Prof. Ah-Ng Tony Kong
Department of Pharmaceutics
Center for Cancer Prevention Research
Ernest-Mario School of Pharmacy
Rutgers, the State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854

E-mail: kongt@pharmacy.rutgers.edu

Prof. Rong Hu
Department of Physiology
School of Pharmacy
China Pharmaceutical University
24 Tongjiqiang
Nanjing 210009
China

E-mail: michelhu@hotmail.com

Dr. Rong Yu
Department of Neurosurgery
The Vivian L. Smith Center for Neurologic Research
The University of Texas-Health Science Center at Houston
6431 Fannin St., Room 7.134
Houston, TX 77030

E-mail: rong.yu@uth.tmc.edu

Date of first submission to ARS Central, April 30, 2010; date of final revised submission, May 8, 2010; date of acceptance, May 9, 2010.

Abbreviations Used

ACF = aberrant crypt foci
 AOM = azoxymethane
 ARE = antioxidant responsive element
 BaP = benzo[*a*]pyrene
 BBN = *N*-nitrosobutyl(4-hydroxybutyl)amine
 bNLS = bipartite nuclear localization signal at the basic region
 BTB = broad complex, tramtrack, and bric a brac
 bZip = basic-leucine zipper
 CNC = Cap 'n' Collar
 CRC = colorectal cancer
 CTR = C-terminal region
 D3T = 3*H*-1,2-dithiole-3-thione
 DGR = double glycine/Kelch repeat region
 DLG = (formulated as) L-X-X-Q-D-X-D-L-G
 DMBA = 7,12-dimethylbenz(a)anthracene
 DSS = dextran sulfate sodium
 EGFP = green fluorescence protein
 ERK2 = extracellular signal-regulated protein kinase 2
 ETGE = (formulated as) D/N-X-E-T/-S-G-E
 fNrf2 = free-floating Nrf2
gpt = guanine phosphoribosyltransferase
GST = glutathione S-transferase
HO-1 = heme oxygenase-1
 IQ = 2-amino-3-methylimidazo[4,5-*f*]quinoline
 IVR = intervening region
 JNK1 = c-Jun NH(2)-terminal kinase-1
 Keap1 = Kelch-like ECH-associated protein 1
 kNrf2 = Keap1-binding Nrf2
 Maf = musculoaponeurotic fibrosarcoma
 MAPKs = mitogen-activated protein kinases
 Neh = Nrf2-ECH homology
 NES = nuclear exporting signal
 NES_{TA} = nuclear exporting signal at transactivation (TA) domain
 NESzip = nuclear exporting signal in the ZIP dimerization domain
 NF- κ B = nuclear factor-kappa-B
 NLS = nuclear localization signal
 NLS_C = monopartite NLS at the carboxyl-terminus
 NLS_N = monopartite NLS at the amino-terminus
 NQO1 = NAD(P)H:quinone oxidoreductase 1
 Nrf2 = NF-E2-related factor 2
 Nrf2 KO = Nrf2 knockout
 Nrf2 WT = wild-type mice with intact Nrf2 function
 NTR = N-terminal region
 PCa = prostate cancer
 PERK = PKR-like endoplasmic reticulum kinase
 PI3K = phosphatidylinositol 3-kinase
 PIN = prostatic intraepithelial neoplasia
 PKC = protein kinase C
 Rb = retinoblastoma
 RNS = reactive nitrogen species
 ROS = reactive oxygen species
 SFN = sulforaphane
 SV40 = simian virus 40
 tBHQ = *tert*-butylhydroquinone
 TPA = 12-O-tetradecanoylphorbol-13-acetate
 TRAMP = transgenic adenocarcinoma mouse prostate
 Ub = ubiquitination
 UGT = UDP-glucuronosyltransferase